David Sass, MD
Gastroenterology · Philadelphia, PANPI 1730154774
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,500 of the $5,112 with a category attached, or 88.0%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 88.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $2,073 and has fallen 92.9% since, to $147 in 2025.
Across 13 payments — averaging $393.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
- Fujifilm Healthcare Americas Corporation$281
- Gilead$147
- Mallinckrodt Enterprises LLC$73
- Johnson & Johnson$31
- Protega Pharmaceutials Inc$20
- plus $62 from 4 others
Across 30 payments — averaging $4660.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$95K
- Ipsen Pharma SAS$36K
- Mallinckrodt Hospital Products Inc.$7K
- Mallinckrodt Enterprises LLC$2K
What the payments were for
- Speaking & faculty fees$4,50088%
- Food & beverage$61212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $4,500 |
| Fujifilm Healthcare Americas Corporation | 1 | $281 |
| Gilead | 1 | $147 |
| Mallinckrodt Enterprises LLC | 1 | $73 |
| Johnson & Johnson | 1 | $31 |
| Protega Pharmaceutials Inc | 1 | $20 |
| AbbVie | 1 | $20 |
| Merck | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $14 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,112 in reported general payments places this provider in the 65th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 93 | $306,609 |
| OcalivaObeticholic Acid | 17 | $196,996 |
| VemlidyTenofovir Alafenamide | 85 | $130,402 |
| RezdiffraResmetirom | 18 | $103,713 |
| Tacrolimus | 272 | $48,831 |
| Sirolimus | 42 | $26,683 |
| Ursodiol | 173 | $25,079 |
| Envarsus XrTacrolimus | 25 | $19,807 |
| Entecavir | 50 | $19,423 |
| Tenofovir Disoproxil Fumarate | 65 | $6,842 |
| Mycophenolate Mofetil | 53 | $4,434 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $3,265 |
| Nadolol | 21 | $2,951 |
| Pantoprazole Sodium | 140 | $1,683 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $1,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $4,500 | $306,60993 claims |
| GileadVemlidy | $147 | $130,40285 claims |
| Madrigal PharmaceuticalsRezdiffra | $14 | $103,71318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Philadelphia
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Gregory GinsbergPhiladelphia$234K
- Neilanjan NandiPhiladelphia$209K
- David LichtensteinPhiladelphia$192K
- Alexander SchlachtermanPhiladelphia$188K
- Kuchikala ReddyPhiladelphia$182K
- James LewisPhiladelphia$175K
- Beth GardnerPhiladelphia$122K
- Gary FalkPhiladelphia$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.